Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/8whN2I1hXh https://t.co/voSVzPQWUI
Links:
Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatom…
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-025-03675-9
24-11-2025


